William P. Petros, Pharm. D, FCCP

Professor and Mylan Chair of Pharmacology

Associate Director for Anti-Cancer Drug Development, Mary Babb Randolph Cancer Center

Department of Basic Pharmaceutical Sciences
West Virginia University
P.O. Box 9530
Morgantown, WV 26506-9530

Phone: (304)293.0495
Fax: (304)293.4667
E-Mail: wpetros@hsc.wvu.edu
Link to CV
 

Education:

Practice Interests:

Research Interests:

Clinical drug development in oncology
Pharmacokinetics and pharmacodynamics of new anti-cancer agents
Clinical pharmacology of hematopoietic growth factors
Pharmacogenomics

Selected Recent Publications:

Younis IR, Malone S, Friedman HS, Schaaf LJ, Petros WP. Enterohepatic recirculation model of irinotecan (CPT-11) & metabolite pharmacokinetics in patients with glioma. Cancer Chemother Pharmacol 2009;63:517-524

Rao AV, Younis IR, Sand GJ, Spasojevic I, Adams DJ, Decastro CM, Gockerman JP, Peterson BL, Petros WP, Moore JO, Rizzieri DA. Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 2008;49:1523-1529.

Younis IR, Elliott M, Peer CJ, Cooper AJL, Pinto JT, Konat GW, Kraszpulski M, Petros WP, Callery PS. Dehydroalanine analog of glutathione: An electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1. J Pharmacol Exp Ther 2008;327:770-776.

Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros WP, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008;14:6270-6276.

Beasley GM, Petersen RP, Yoo J, McMahon N, Aloia T, Petros WP, Sanders G, Cheng TY, Pruitt SK, Seigler H, Tyler DS. Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion. Ann Surg Oncol 2008;15:2195-2205.

Cooper AJL, Younis IR, Niatsetskaya ZV, Krasnikov BF, Pinto JT, Petros WP, Callery PS. Metabolism of the cysteine S-conjugate of busulfan involves a ß-lyase reaction. Drug Metabol Dispos 2008;36:1546-52.

Czito BG, Cohen DP, Kelsey CR, Lockhart AC, Bendell JC, Willett CG, Petros WP, D'Amico TA, Truax R, Hurwitz HI. A Phase I Study of UFT/Leucovorin, Carboplatin, and Paclitaxel in Combination with External Beam Radiation Therapy for Advanced Esophageal Carcinoma. Int J Radiat Oncol Biol Phys 2008;70:1066-1072

Petros WP & Craig M. Hematopoiesis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach, Lippincott, Williams & Wilkins. Seventh Edition, 1627-1638, 2008.

Hurwitz HL, Cohen RB, McGovern JP, Hirawat S, Petros WP, Natsumeda Y, Yoshinari T. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2007;59:139-147.

Petros WP. Hematopoietic Growth Factors. In: Chabner BA & Longo DA, eds. Cancer Chemotherapy and Biotherapy: Principles & Practice. Philadelphia: JB Lippincott, 4th Edition, pp 747-766, 2006.

Vredenburgh JJ, Coniglio D, Broadwater G, Jones RB, Ross M, Shpall EJ, Hussein A, Rizzieri D, Marks LB, Gilbert C, Affronti ML, Moore S, McDonald C, Petros WP, Peters WP. Consolidation with High-dose Combination Alkylating Agents with Bone Marrow Transplantation Significantly Improves Disease-free Survival in Hormone-insensitive Metastatic Breast Cancer in Complete Remission Compared to Intensive Standard-dose Chemotherapy Alone. Biol Blood Marrow Transplant 2006 Feb;12(2):195-203.

Czito BG, Hong TJ, Cohen DP, Petros WP, Tyler DS, Pappas TN, Yu D, Lee CG, Lockhart AC, Morse MA, Fernando N, Hurwitz HI. A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract. Cancer Invest 2006 Feb;24(1):9-17.

Cox MC, Low J, Lee J, Walshe J, Denduluri N, Berman A, Permenter MG, Petros WP, Price DK, Figg WD, Sparreboom A, Swain SM.Clin Cancer Res. 2006 Aug 1;12(15):4636-40. Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel. Clin Cancer Res 2006;12:4636-40.

Hauck, ML, LaRue SM, Petros WP, Poulson JM, Yu D, Spasojevic I, Pruitt AF, Klein A, Case B, Thrall DE, Needham D, Dewhirst MW. Phase I trial of doxorubicin-containing low-temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res 2006;12:4004-4010.

Petros WP & Evans WE. Anti-Cancer Agents. In: Schentag JJ, Evans WE, Burton ME, eds. Applied Pharmacokinetics & Pharmacodynamics, Lippincott, Williams & Wilkins. Fourth Edition, pp 617-636, 2006.

Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, Bomgaars L, Blaney SM, Kun LE, Boyett JM. Phase I trial of intrathecal Spartaject busulfan in children with neoplastic meningitis: a pediatric brain tumor consortium study (PBTC-004). Clin Cancer Res 2006;12:1540-1546.

Professional Memberships:

American Association for Cancer Research
American Society of Clinical Oncology
Mary Babb Randolph / West Virginia University Cancer Center
Duke Comprehensive Cancer Center
American College of Clinical Pharmacy